346 related articles for article (PubMed ID: 33958325)
1. Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial.
Molto A; López-Medina C; Van den Bosch FE; Boonen A; Webers C; Dernis E; van Gaalen FA; Soubrier M; Claudepierre P; Baillet A; Starmans-Kool M; Spoorenberg A; Jacques P; Carron P; Joos R; Lenaerts J; Gossec L; Pouplin S; Ruyssen-Witrand A; Sparsa L; van Tubergen A; van der Heijde D; Dougados M
Ann Rheum Dis; 2021 Nov; 80(11):1436-1444. PubMed ID: 33958325
[TBL] [Abstract][Full Text] [Related]
2. Clinical performance of ASAS Health Index in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: real-world evidence from Multicenter Nationwide Registry.
Akgul O; Bodur H; Ataman S; Yurdakul FG; Capkin E; Gurer G; Sezer I; Duruoz MT; Melikoglu MA; Cay HF; Rezvani A; Yagci I; Gogus F; Kamanli A; Cevik R
Rheumatol Int; 2020 Nov; 40(11):1793-1801. PubMed ID: 32814986
[TBL] [Abstract][Full Text] [Related]
3. Treat-to-target strategy with secukinumab as a first-line biological disease modifying anti-rheumatic drug compared to standard-of-care treatment in patients with active axial spondyloarthritis: protocol for a randomised open-label phase III study, AScalate.
Poddubnyy D; Hammel L; Heyne M; Veit J; Jentzsch C; Baraliakos X
BMJ Open; 2020 Sep; 10(9):e039059. PubMed ID: 32998926
[TBL] [Abstract][Full Text] [Related]
4. Treat-to-target dose reduction and withdrawal strategy of TNF inhibitors in psoriatic arthritis and axial spondyloarthritis: a randomised controlled non-inferiority trial.
Michielsens CA; den Broeder N; van den Hoogen FH; Mahler EA; Teerenstra S; van der Heijde D; Verhoef LM; den Broeder AA
Ann Rheum Dis; 2022 Oct; 81(10):1392-1399. PubMed ID: 35701155
[TBL] [Abstract][Full Text] [Related]
5. Treat to Target in Axial Spondyloarthritis: What Are the Issues?
Danve A; Deodhar A
Curr Rheumatol Rep; 2017 May; 19(5):22. PubMed ID: 28386759
[TBL] [Abstract][Full Text] [Related]
6. Treat-to-target in axial spondyloarthritis: gold standard or fools' gold?
Machado PM; Deodhar A
Curr Opin Rheumatol; 2019 Jul; 31(4):344-348. PubMed ID: 31090589
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1).
Sieper J; van der Heijde D; Dougados M; Mease PJ; Maksymowych WP; Brown MA; Arora V; Pangan AL
Ann Rheum Dis; 2013 Jun; 72(6):815-22. PubMed ID: 22772328
[TBL] [Abstract][Full Text] [Related]
8. Tumour necrosis factor-α inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation.
Corbett M; Soares M; Jhuti G; Rice S; Spackman E; Sideris E; Moe-Byrne T; Fox D; Marzo-Ortega H; Kay L; Woolacott N; Palmer S
Health Technol Assess; 2016 Feb; 20(9):1-334, v-vi. PubMed ID: 26847392
[TBL] [Abstract][Full Text] [Related]
9. Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA.
van der Heijde D; Dougados M; Landewé R; Sieper J; Maksymowych WP; Rudwaleit M; Van den Bosch F; Braun J; Mease PJ; Kivitz AJ; Walsh J; Davies O; Bauer L; Hoepken B; Peterson L; Deodhar A
Rheumatology (Oxford); 2017 Sep; 56(9):1498-1509. PubMed ID: 28498975
[TBL] [Abstract][Full Text] [Related]
10. Is fibromyalgia frequency increasing in axial spondyloarthritis? Association with fibromyalgia and biological therapies.
Sayın S; Yurdakul FG; Sivas F; Bodur H
Rheumatol Int; 2020 Nov; 40(11):1835-1841. PubMed ID: 32767083
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Non-radiographic Axial Spondyloarthritis and Ankylosing Spondyltis from a Single Rheumatology Hospital in Morocco.
Akasbi N; Nihad S; Sofia Z; Khadija EK; Taoufik H
Curr Rheumatol Rev; 2020; 16(3):240-244. PubMed ID: 30806321
[TBL] [Abstract][Full Text] [Related]
12. Treating to the target of remission in early rheumatoid arthritis is cost-effective: results of the DREAM registry.
Vermeer M; Kievit W; Kuper HH; Braakman-Jansen LM; Bernelot Moens HJ; Zijlstra TR; den Broeder AA; van Riel PL; Fransen J; van de Laar MA
BMC Musculoskelet Disord; 2013 Dec; 14():350. PubMed ID: 24330489
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE study.
Dougados M; Wood E; Combe B; Schaeverbeke T; Miceli-Richard C; Berenbaum F; Koppiker N; Dubanchet A; Logeart I
Arthritis Res Ther; 2014 Nov; 16(6):481. PubMed ID: 25428762
[TBL] [Abstract][Full Text] [Related]
14. Clinimetric Validation of the Assessment of Spondyloarthritis International Society Health Index in Patients With Radiographic Axial Spondyloarthritis in Ixekizumab Trials.
Kiltz U; van der Heijde D; Boonen A; Gensler LS; Gibble TH; Guo J; Carlier H; Braun J
J Rheumatol; 2023 Jun; 50(6):754-762. PubMed ID: 36725056
[TBL] [Abstract][Full Text] [Related]
15. Similar biologic drug response regardless of radiographic status in axial spondyloarthritis: data from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis registry.
Michelena X; Zhao SS; Dubash S; Dean LE; Jones GT; Marzo-Ortega H
Rheumatology (Oxford); 2021 Dec; 60(12):5795-5800. PubMed ID: 33502476
[TBL] [Abstract][Full Text] [Related]
16. Impaired response to treatment with tumour necrosis factor α inhibitors in smokers with axial spondyloarthritis.
Ciurea A; Scherer A; Weber U; Exer P; Bernhard J; Tamborrini G; Riek M; Müller RB; Weiss B; Nissen MJ; Kissling R; Michel BA; Finckh A;
Ann Rheum Dis; 2016 Mar; 75(3):532-9. PubMed ID: 25667205
[TBL] [Abstract][Full Text] [Related]
17. Effect of biologic disease-modifying anti-rheumatic drugs targeting remission in axial spondyloarthritis: systematic review and meta-analysis.
Cruz-Machado AR; Rodrigues-Manica S; Silva JL; Alho I; Coelho C; Duarte J; Florêncio C; Pimentel-Santos FM; Tavares-Costa J; Vieira-Sousa E
Rheumatology (Oxford); 2020 Nov; 59(11):3158-3171. PubMed ID: 32696064
[TBL] [Abstract][Full Text] [Related]
18. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
Brown S; Everett CC; Naraghi K; Davies C; Dawkins B; Hulme C; McCabe C; Pavitt S; Emery P; Sharples L; Buch MH
Health Technol Assess; 2018 Jun; 22(34):1-280. PubMed ID: 29900829
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and drug retention of biologic disease modifying antirheumatic drugs in Korean patients with late onset ankylosing spondylitis.
Kim SH; Kim HR; Lee SH; Shin K; Kim HA; Min HK
Sci Rep; 2021 Nov; 11(1):21555. PubMed ID: 34732807
[TBL] [Abstract][Full Text] [Related]
20. Predictors of remission in patients with non-radiographic axial spondyloarthritis receiving open-label adalimumab in the ABILITY-3 study.
Sieper J; Landewé R; Magrey M; Anderson JK; Zhong S; Wang X; Lertratanakul A
RMD Open; 2019; 5(1):e000917. PubMed ID: 31245052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
